P21 (P021) 5mg

Description:

P021, also known as P21 peptide, is a synthetic peptide derived from the p21 protein. The p21 protein, also called cyclin-dependent kinase inhibitor 1 (CDKN1A), is a key regulator of cell cycle progression and acts as a tumor suppressor. It is involved in cell cycle arrest and DNA repair mechanisms.
Research involving P021 peptide primarily focuses on its potential therapeutic applications, particularly in cancer treatment. In animal studies, P21 has demonstrated the ability to increase levels of BDNF (brain-derived neurotrophic factor), which supports neurogenesis while also inhibiting the formation of Amyloid plaques and Tau proteins commonly associated with Alzheimer’s disease. BDNF has been found to not only promote neurogenesis but also downregulate specific enzymes responsible for the formation of tau and amyloid plaques in the brains of individuals with Alzheimer’s. Additionally, P21 has been observed to enhance cognitive function in animal models.

P21 Research:

Here are some areas of research related to P021 peptide:

• Anti-cancer properties: P021 peptide has been studied for its ability to inhibit cancer cell growth and induce cell cycle arrest. It has shown promising results in preclinical studies, where it demonstrated anti-tumor activity against various types of cancer, including breast cancer, lung cancer, and prostate cancer.
• Combination therapy: P021 peptide has been investigated in combination with other anticancer agents to enhance treatment efficacy. For example, combining P021 with chemotherapeutic drugs or targeted therapies has shown synergistic effects in inhibiting tumor growth and improving overall treatment outcomes.
• Radiosensitization: Radiation therapy is a common treatment for cancer, and P021 peptide has been explored as a potential radiosensitizer. It can sensitize cancer cells to radiation-induced DNA damage, leading to increased cell death and improved radiation therapy outcomes.
• Drug delivery systems: P021 peptide has also been utilized in the development of drug delivery systems for targeted therapy. By conjugating therapeutic agents or nanoparticles with P021 peptide, researchers aim to improve drug delivery specifically to cancer cells, reducing off-target effects and enhancing treatment efficacy.
• Mechanisms of action: Researchers continue to investigate the molecular mechanisms through which P021 peptide exerts its anti-cancer effects. This knowledge can provide insights into its mode of action and potential targets for further therapeutic development.
• Cognitive improvement: In some studies, P021 peptide administration has been associated with cognitive improvement in animal models of Alzheimer’s disease. Improved performance in memory and learning tasks has been observed, suggesting a potential therapeutic benefit in terms of cognitive function.